AbbVie/Roche CLL drug venetoclax deemed 'breakthrough'
This article was originally published in Scrip
Executive Summary
The FDA has granted breakthrough therapy designation (BTD) to AbbVie's venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein, which the company is developing in partnership with Roche and its US subsidiary Genentech as a treatment for chronic lymphocytic leukemia (CLL) in relapsed/refractory patients with the 17p deletion genetic mutation.